Fuxiang Pharmaceutical was criticized in the circular due to the issue of letter disclosure, and the performance will be expressed or re-introduced to investors' "reverie".

Post date May 13, 2022 — 01:11 Post Lock

Key Data Concepts:
? These are the company names, stock quotes, topics, and entities related to this data.

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Related Data

Don't be afraid of fluctuations! The April list of the 2nd "Jinhua Cai Cup" Private Equity Competition of West China Securities was released

May 20, 2022 — 18:00

Asia Potash International: There is no exchange gain or loss problem

May 20, 2022 — 17:57

Kangtai Medical: The company's decline in sales of blood oxygen products in 2021 is mainly affected by changes in demand and the high base of the previous year

May 20, 2022 — 17:56

Hualin Securities (002945): CITIC Securities Co., Ltd. Report on Interim Trustee Management Affairs of Hualin Securities Co., Ltd. on the Change of Directors- CFi.CN Zhongcai.com

May 20, 2022 — 17:56

Oxycon (002913): Announcement on the progress of Oxycon Technology Co., Ltd. on the use of some idle self-owned funds for cash management- CFi.CN Zhongcai Network

May 20, 2022 — 17:56

TANSUN: The company's business is stable, the orders on hand are sufficient, and the number of employees has maintained an increasing trend compared with the beginning of the year

May 20, 2022 — 17:55

Junda Co., Ltd. (002865): Completed industrial and commercial change registration CFi.CN Zhongcai Network

May 20, 2022 — 17:55

List of medium-term notes issuance schedule in China's bond market (May 20)

May 20, 2022 — 17:55

Yanao Co., Ltd.: The company's fundraising project "High-speed Rail Maintenance Production Line Upgrade and Reconstruction Project" obtained the construction project planning permit on July 28, 2021

May 20, 2022 — 17:54

Home » News » Fuxiang Pharmaceutical was criticized in the circular due to the issue of letter disclosure, and the performance will be expressed or re-introduced to investors' "reverie".